French biopharma developer Synthelis secures seed investment

French biopharmaceutical developer Synthelis has secured initial backing of €610,000 from investors comprising Rhone-Alpes Creation, Alpes Developpement Durable Investissement (A2D-Invest), Sud Rhone-Alpes Capital, Viaduc and the Savoy and Grenoble Business Angels networks.